Protalix Plans US Resubmission For ERT For Fabry After Positive Phase III Trial Results
You may also be interested in...
Chiesi's Commercial Hopes In US Hit By FDA Letter
Shares in Protalix sank more than 30% after the company received a complete response letter from US regulators for pegunigalsidase alfa for Fabry disease. No inspection of the company's manufacturing plant in Israel appears to be the main sticking point.
Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.